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Abstract
Background: The use of hydroxocobalamin has long been advocated for treating suspected cyanide poisoning
after smoke inhalation. Intravenous hydroxocobalamin has however been shown to cause oxalate nephropathy in a
single-center study. The impact of hydroxocobalamin on the risk of acute kidney injury (AKI) and survival after
smoke inhalation in a multicenter setting remains unexplored.
Methods: We conducted a multicenter retrospective study in 21 intensive care units (ICUs) in France. We included
patients admitted to an ICU for smoke inhalation between January 2011 and December 2017. We excluded patients
discharged at home alive within 24 h of admission. We assessed the risk of AKI (primary endpoint), severe AKI,
major adverse kidney (MAKE) events, and survival (secondary endpoints) after administration of hydroxocobalamin
using logistic regression models.
Results: Among 854 patients screened, 739 patients were included. Three hundred six and 386 (55.2%) patients
received hydroxocobalamin. Mortality in ICU was 32.9% (n = 243). Two hundred eighty-eight (39%) patients
developed AKI, including 186 (25.2%) who developed severe AKI during the first week. Patients who received
hydroxocobalamin were more severe and had higher mortality (38.1% vs 27.2%, p = 0.0022). The adjusted odds ratio
(95% confidence interval) of AKI after intravenous hydroxocobalamin was 1.597 (1.055, 2.419) and 1.772 (1.137,
2.762) for severe AKI; intravenous hydroxocobalamin was not associated with survival or MAKE with an adjusted
odds ratio (95% confidence interval) of 1.114 (0.691, 1.797) and 0.784 (0.456, 1.349) respectively.
Conclusion: Hydroxocobalamin was associated with an increased risk of AKI and severe AKI but was not associated
with survival after smoke inhalation.
Trial registration: ClinicalTrials.gov, NCT03558646
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Introduction
Patients with smoke inhalation are at a high risk of
death or major morbidities. Cyanide is a documented
cause for rapid death after intoxication from smoke
[1]. Several cyanide antidotes have been proposed
(i.e., sodium nitrite, amyl nitrite, sodium thiosulfate,
4-dimethylaminophenol, dicobalt edetate, and hydro-
xocobalamin) with utilization varying across countries
[2]. Several experts suggested using hydroxocobalamin
as the first-line treatment after suspected cyanide in-
toxication due to its perceived good safety profile [3].
However, other experts raised concerns about liberal-
izing the use of hydroxocobalamin after smoke inhal-
ation due to a lack of data on both efficacy and
tolerance. They have called for additional investiga-
tions [4, 5].
Recently, nephrotoxicity of hydroxocobalamin due to
oxalate nephropathy was reported in a single-center
study among burn patients [4]. The objective of this co-
hort study was to assess the association between the use
of hydroxocobalamin and the risk of acute kidney injury
(AKI) and death in intensive care unit (ICU) patients
with smoke inhalation.
Methods
Study population and settings
We conducted a retrospective, multicenter study in
21 ICUs in France. All consecutive adult (≥ 18 years
old) patients admitted between January 2011 and De-
cember 2017 with the final diagnosis of smoke inhal-
ation were included in this study. Patients discharged
alive at home within 24 h from admission (reflecting
absence of severity) were excluded. Patient files were
retrieved using our national coding for smoke inhal-
ation injury (code CIM T599 for all patients and as-
sociated: X00·0, X 09·0, X09·9, X47·0, X47·08, X47·9,
X67·0, X67·9, T58) (Additional file 1: Table S1). This
academic investigator-driven study was registered at
ClinicalTrials.gov, NCT03558646. The study protocol
was approved by our local research ethical committee
(Comité de Protection des Personnes 2013/17NICB).
The use of patient’s data was allowed in cases of
death and/or when proxies could not be contacted.
Primary outcome
The primary outcome was AKI. AKI was defined accord-
ing to Kidney Disease Improving Global Outcome
(KDIGO) within 7 days following admission using the
serum creatinine criteria [6].
Secondary outcome
Secondary outcomes were severe AKI (severe AKI defined
patients by AKI stage 2 or 3), major associated kidney
events (MAKE) in the ICU, which includes death and/or
renal replacement therapy (RRT), and/or persistent AKI at
ICU discharge. Persistent AKI was defined as an elevated
SCreat level from baseline by > 1.5-fold or > 0.3 mg/dL
(26.3 μmol/L) at ICU discharge or RRT at ICU discharge
and survival in the ICU.
Data collections and definitions
Data were collected through a standardized case re-
port form. Each form was manually encoded in each
participating center using the initials and year of birth
of the patient. Admission serum creatinine (SCreat)
was used for baseline SCreat. Severe burn was defined
as total body surface area (TBSA) burn ≥ 20% and/or
deep TBSA burn ≥ 10% with organ support on admis-
sion (i.e., mechanical ventilation or need for vasopres-
sors) [7]. When a fiber-optic bronchoscopy was
performed, inhalation injury was classified according
to fiber-optic bronchoscopy inhalation injury classifi-
cation [8].
Sample size and statistical analysis
Due to the exploratory design of this study, no sam-
ple size could be calculated. Categorical variables
were presented using percentages and counts, and
continuous variables were presented using means and
standard deviations or medians with the 25th and
75th percentiles. Categorical variables were compared
using the chi-square test or Fisher’s exact test as ap-
propriate. Continuous variables were compared using
the Student t test or the Mann–Whitney U test as
appropriate.
Actuarial mortality was plotted using the Kaplan–
Meier estimator. Administrative censoring was applied
at day 90. The impact of hydroxocobalamin adminis-
tration on AKI was estimated using a multivariate lo-
gistic regression model adjusting age, comorbidities,
aminoglycoside, vancomycin and iodine contrast agent
utilization during hospitalization, peak value of cre-
atinine phosphokinase, prehospital cardiac arrest, pre-
hospital minimal GCS, severe burn, initial sequential
organ failure assessment (SOFA) score without the
renal item, lactate at admission, need for catechol-
amine infusion at admission, the SAPS2 score calcu-
lated over the first 24 h, the interaction between
hydroxocobalamin administration and prehospital car-
diac arrest, and the center. The impact of hydroxoco-
balamin administration on secondary outcomes
(severe AKI, MAKE, survival) was estimated using a
multivariate logistic regression model adjusting for
the same confounders. An interaction term between
prehospital cardiac arrest and hydroxocobalamin was
also introduced in the model. Odds ratios were pro-
vided together with their 95% confidence intervals.
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Table 1 Comparison between patients with or without hydroxocobalamin
Characteristics All patients, N = 739 Hydroxocobalamin, N = 386 No hydroxocobalamin, N = 353 p
At admission
- Age in years 50 (36–63) 50 (38–62) 48 (33–64) 0.4858
- Sex female, n (%) 271 (36.7) 140 (36.3) 131 (37.1) 0.9335
- BMI in kg/m2 25 (22–28) 24 (22–28) 25 (22–28) 0.2416
- Prehospital cardiac arrest (%) 46 (6.2) 42 (10.9) 4 (1.1) < 0.0001
- Prehospital GSC /15 15 (9–15) 13 (5–15) 15 (14–15) < 0.0001
Comorbidities
- CKD, n (%) 6 (0.8) 6 (1.6) 0 (0) 0.0315
- CHT, n (%) 141 (19.1) 71 (18.4) 70 (19.9) 0.6872
- Diabetes mellitus, n (%) 54 (7.3) 33 (8.5) 21 (6) 0.2243
- Peripheral artery disease, n (%) 22 (3) 9 (2.3) 13 (3.7) 0.3882
- CHF, n (%) 33 (4.5) 20 (5.2) 13 (3.7) 0.4197
Burn characteristic
- Burn, n (%) 577 (78.1) 286 (74.1) 291 (82.4) 0.0081
- TBSA % 20 (3–47) 15 (0–45) 24 (6–50) 0.0163
- Deep burn TBSA % 9 (0–30) 5 (0–30) 10 (0–32) 0.1985
SOFA at admission 4 (1–7) 5 (2–8) 2 (0–5) < 0.0001
MAP in mmHg 86 (72–101) 86 (68–101) 86 (73–101) 0.4383
Vasopressors, n (%) 226 (30.6) 153 (39.6) 73 (20.7) < 0.0001
HbCO % 3.6 (1.9–9.7) 7 (3–15) 3 (2–5) < 0.0001
Biological data
- Plasma lactate in mmol/L 3.0 (1.8–5.2) 3.5 (2.1–6) 2.6 (1.4–4.1) < 0.0001
- Serum creatinine at admission in μmol/L 76 (59–101) 82 (63–106) 71 (56–93) 0.0031
- Maximal serum creatinine in μmol/L 100 (73–162) 108 (77–182) 90 (71–137) 0.0027
Inhalation fibroscopic status, n (%) 305 (41.3) 105 (27.5) 200 (56.7) < 0.0001
- Grade 0, n 1 (0.1) 0 (0) 1 (0.3) 1
- Grade 1, n 121 (16.4) 31 (8) 90 (25.5) < 0.0001
- Grade 2, n 110 (14.9) 37 (9.6) 73 (20.7) < 0.0001
- Grade 3, n 73 (9.9) 37 (9.6) 36 (10.2) 0.8764
During ICU hospitalization
- In-ICU mortality, n (%) 243 (32.9) 147 (38.1) 96 (27.2) 0.0022
- AKI in the first week, n (%) 288 (39) 166 (43) 122 (34.6) 0.0229
- Stage of AKI
- Stage 1, n (%) 102 (13.8) 52 (13.5) 50 (14.2) 0.8682
- Stage 2, n (%) 39 (5.3) 22 (5.7) 17 (4.8) 0.7099
- Stage 3, n (%) 147 (19.9) 92 (23.8) 55 (15.6) 0.0066
- Severe AKI, n (%) 186 (25.2) 114 (29.5) 72 (20.4) 0.0055
RRT at day 7, n (%) 136 (18.8) 86 (22.3) 50 (14.2) 0.006
- RRT in ICU, n (%) 183 (24.8) 107 (27.7) 76 (21.5) 0.0626
- MAKE, n (%) 313 (42.4) 187 (48.4) 126 (35.7) 0.0006
- Shock in ICU, n (%) 402 (54.4) 225 (58.3) 176 (50) 0.0261
- Length of stay in ICU in days 15 (3–44) 11 (2–36) 22 (3–50) 0.0161
- SAPS2 42 (27–60) 49 (31–77) 37 (23–54) < 0.0001
- In-ICU survival, n (%) 496 (67.1) 239 (61.9) 257 (72.8) 0.0022
Nephrotoxic in ICU
- Aminoglycoside during hospitalization 188 (25.4) 81 (21) 107 (30.3) 0.0047
- Glycopeptide during hospitalization 41 (5.5) 16 (4.1) 25 (7.1) 0.1138
- Contrast agent 74 (10) 48 (12.4) 26 (7.4) 0.0299
All data are expressed as median ± 25–75 interquartile or percentage (%)
BMI body mass index, GCS Glasgow coma scale, CKD chronic kidney disease, CHT chronic hypertension, CHF chronic heart failure, TBSA total body surface area, SOFA sequential organ
failure assessment, MAP mean arterial pressure, HbCO carboxy hemoglobin, ICU intensive care unit, AKI acute kidney injury, Severe AKI AKI stage 2 and 3, RRT renal replacement therapy,
MAKE major associated kidney events, Shock in ICU catecholamine need during ICU stay, SAPS2 simplified acute physiology score 2
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Table 2 Multivariate analyses of factors associated with AKI and severe AKI
Variable Adjusted odds ratio LCI UCI p
AKI
Hydroxocobalamin 1.597 1.055 2.419 0.027
Severe burn 2.91 1.841 4.601 < 0.001
SOFA score without renal item 1.003 0.891 1.129 0.963
Prehospital GCS 1.064 0.997 1.136 0.063
Aminoglycoside during hospitalization 2.903 1.184 4.473 < 0.001
Glycopeptide during hospitalization 1.731 0.773 3.877 0.182
Admission plasma lactate 1.105 1.034 1.182 0.003
Age 1.009 0.997 1.021 0.154
Peripheral arterial obstructive disease 0.913 0.308 2.713 0.87
Diabetes mellitus 1.487 0.726 3.046 0.278
Chronic hypertension 2.134 1.248 3.649 0.006
CKD 0.947 0.119 7.504 0.959
Prehospital cardiac arrest 0.418 0.025 7.096 0.546
Vasopressor at admission 1.778 0.93 3.396 0.081
Maximum CPK 1.081 0.997 1.242 0.269
Contrast agent 1.445 0.803 2.601 0.219
SAPS2 1.021 1.006 1.036 0.009
Center 1.014 0.976 1.053 0.484
Interaction between prehospital cardiac arrest and hydroxocobalamin 2.245 0.125 40.367 0.583
Severe AKI
Hydroxocobalamin 1.772 1.137 2.762 0.012
Age 1.006 0.993 1.019 0.394
Peripheral arterial obstructive disease 0.552 0.183 1.668 0.292
Diabetes mellitus 1.201 0.582 2.479 0.619
Chronic hypertension 2.045 1.168 3.579 0.012
Prehospital cardiac arrest 0.775 0.043 14.12 0.863
Severe burn 2.157 1.276 3.645 0.004
SOFA score at admission without renal item 1.047 0.924 1.185 0.471
CKD 2.407 0.285 20.299 0.418
Vasopressor at admission 1.298 0.653 2.579 0.456
Prehospital GCS 1.04 0.973 1.11 0.248
Admission plasma lactate 1.151 1.062 1.248 0.001
Maximum CPK 1.099 0.904 1.337 0.324
Aminoglycoside during hospitalization 2.418 1.539 3.801 < 0.001
Contrast agent 0.889 0.476 1.663 0.713
Glycopeptide during hospitalization 2.873 1.318 6.261 0.008
SAPS2 1.02 1.006 1.035 0.006
Center 1.042 0.998 1.089 0.061
Interaction between prehospital cardiac arrest and hydroxocobalamin 0.412 0.02 8.331 0.563
AKI acute kidney injury, LCI lower confidence interval, UCI upper confidence interval, p p value, SOFA score sequential organ failure assessment, GCS Glasgow coma
scale, CKD chronic kidney disease, CPK creatinine phosphokinase, SAPS2 simplified acute physiology score 2
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Missing data were handled using multivariate imput-
ation by chained equations (mice package for R, 50 im-
putations) [9].
Because plasma lactate level was shown to correlate
with cyanide, we performed subgroup analysis in pa-
tients with plasma lactate level at admission above me-
dian of the entire cohort and above 8 mmol/L [10, 11].
A subgroup analysis was also performed in patients with
severe burns.
Results
Among 854 patients with smoke inhalation, 739 were
included in the analysis after exclusion of patients
discharged at home within 24 h. Three hundred
eighty-six (55.2%) patients received hydroxocobalamin.
Patient’s characteristics and comparison between pa-
tients who received hydroxocobalamin and those who
did not are presented in Table 1. The number of pa-
tients per center is summarized in Additional file 2:
Table S2.
Acute kidney injury
Two hundred eighty-eight (39%) patients developed
AKI in the first week, including 186 (25.2%) patients
with severe AKI. In univariate analysis, the use of
hydroxocobalamin was associated with AKI, severe
AKI, and RRT (Table 1). After adjusting for potential
confounders, hydroxocobalamin remained associated
with AKI and severe AKI and RRT (Table 2, Fig. 1
and Additional file 3: Table S3). Severe burns, amino-
glycoside administration, admission plasma lactate
level, chronic hypertension, and SAPS2 were also as-
sociated with AKI (Table 2).
Three hundred and thirteen (42.4%) patients met
the criteria for MAKE during ICU stay. Hydroxocoba-
lamin was not associated with the risk of MAKE in
multivariate analysis (OR = 0.784, LCI = 0.456, UCI =
1.349, p = 0.379). Factors associated with MAKE in
ICU are summarized in Additional file 4: Table S4.
ICU mortality
Mortality in ICU was 32.9% (N = 243). Patients who
received hydroxocobalamin had higher severity scores
and higher mortality rate. Factors associated with
mortality in univariate analysis are summarized in
Table 3 and Fig. 2. In multivariate analysis, hydroxo-
cobalamin was not associated with survival (OR =
1.114, LCI = 0.691, UCI = 1.797, p = 0.657). Age, severe
burns, SAPS2, plasma lactate level at admission, and
the center were associated with mortality in ICU
(Table 4). Three hundred and ninety-two patients
(53%) had admission plasma lactate level above the
median (median = 3.0 [1.8–5.2] mmol/L), and 74 pa-
tients had admission plasma lactate level ≥ 8 mmol/L
(median = 10.5 [8.9–12.8] mmol/L) (among 681
(92.2%) patients with plasma lactate available at ad-
mission, Additional file 5: Table S5). No association
between hydroxocobalamin use and survival was ob-
served after adjustment for confounding factors in the
subgroups of patients with admission plasma lactate
level above the median (OR = 0.76; LCI = 0.398, UCI =
1.451, p = 0.403) or in the group of patients with ad-
mission plasma lactate level ≥ 8 mmol/L (OR = 2.604,
Fig. 1 Non-adjusted and adjusted odds ratio (lower confidence interval, upper confidence interval) of hydroxocobalamin for AKI (upper panel)
and severe AKI (lower panel). Adjusted on the following variables: age, peripheral arterial obstructive disease, diabetes mellitus, chronic
hypertension, chronic kidney disease, prehospital cardiac arrest, severe burn, SOFA score without kidney item, vasopressors at admission,
prehospital Glasgow coma scale, plasmatic lactate level at admission, maximum creatinine phosphokinase plasmatic level, contrast agent, use of
vancomycin and aminoglycosides, and simplified acute physiology score 2
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Table 3 Patient characteristics
Characteristics All patients, N = 739 Survivors, N = 496 Non-survivors, N = 243 p
At admission
- Age in years 50 (36–63) 46 (33–59) 56 (43–72) < 0.0001
- Sex female, n (%) 271 (36.7) 180 (36.3) 91 (37.4) 0.8214
- BMI in kg/m2 25 (22–28) 24 (22–28) 25 (22–29) 0.0822
- Prehospital cardiac arrest (%) 46 (6.2) 11 (2.2) 35 (14.4) < 0.0001
- Prehospital GSC /15 15 (9–15) 15 (13–15) 14 (3–15) < 0.0001
Comorbidities
- CKD, n (%) 6 (0.8) 2 (0.4) 4 (1.6) 0.0948
- Hypertension, n (%) 141 (19.1) 81 (16.3) 60 (24.7) 0.0088
- Diabetes mellitus, n (%) 54 (7.3) 28 (5.6) 26 (10.7) 0.0198
- CAOD, n (%) 22 (3) 7 (1.4) 15 (6.2) 0.0008
- CHF, n (%) 33 (4.5) 20 (4) 13 (5.3) 0.4858
Burn characteristic
- Burn, n (%) 577 (78.1) 357 (72) 220 (90.5) < 0.0001
- TBSA % 20 (3–47) 12 (0–30) 50 (20–73) < 0.0001
- 3rd degree TBSA % 9 (0–30) 2 (0–15) 33 (10–58) < 0.0001
SOFA at admission 4 (1–7) 2 (1–5) 7 (3–10) < 0.0001
MAP in mmHg 86 (72–101) 89 (76–102) 80 (62–97) < 0.0001
Vasopressor, n (%) 226 (30.6) 90 (18.1) 136 (56) < 0.0001
Hydroxocobalamin, n (%) 386 (52.2) 239 (48.2) 147 (60.5) 0.0021
HbCO % 4 (2–10) 4 (2–11) 3 (2–7) 0.0323
Biological data
- Plasmatic lactate in mmol/L 3.0 (1.8–5.2) 2.5 (1.4–3.8) 4.8 (3–7.6) < 0.0001
- Serum creatinine in μmol/L 76 (59–101) 71 (56–88) 100 (72–123) < 0.0001
- Maximal serum creatinine in μmol/L 100 (73–162) 84 (68–113) 137 (102–212) < 0.0001
Inhalation fibroscopic status (%) 305 (41.3) 175 (35.3) 130 (53.5) < 0.0001
- Grade 0, n 1 (0.1) 1 (0.2) 0 (0) 1
- Grade 1, n 121 (16.4) 90 (18.2) 31 (12.8) 0.0795
- Grade 2, n 110 (14.9) 67 (13.5) 43 (17.7) 0.1638
- Grade 3, n 73 (9.9) 17 (3.4) 56 (23.1) < 0.0001
- During ICU hospitalization
- AKI in the first week, n (%) 288 (39) 126 (25.4) 162 (66.7) < 0.0001
- Stage of AKI day 7
- Stage 1, n (%) 102 (13.8) 63 (12.7) 39 (16) 0.2601
- Stage 2, n (%) 39 (5.3) 16 (3.2) 23 (9.5) 0.0007
- Stage 3, n (%) 147 (19.9) 47 (9.5) 100 (41.2) < 0.0001
- Severe AKI 186 (25.2) 63 (12.7) 123 (50.6) < 0.0001
- RRT at day 7, n (%) 136 (18.8) 44 (8.9) 92 (37.9) < 0.0001
- RRT in ICU, n (%) 183 (24.8) 58 (11.7) 125 (51.4) < 0.0001
- MAKE, n (%) 313 (42.4) 69 (13.9) 243 (100) < 0.0001
- Shock in ICU, n (%) 402 (54.4) 191 (38.5) 211 (86.8) < 0.0001
- Length of stay in ICU 15 (3–44) 25 (4–50) 6 (1–24) 0.0001
- SAPS2 42 (27–60) 32 (22–46) 61 (46–75) < 0.0001
Nephrotoxic in ICU
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LCI = 0.361, UCI = 18.79, p = 0.336). In multivariate
analysis, hydroxocobalamin was neither associated
with survival (OR = 0.85, LCI = 0.5, UCI = 1.447, p =
0.549) among 405 (54.8%) patients with severe burns
(Additional file 6: Table S6).
Discussion
In this retrospective, multicenter study, we observed a
higher risk of AKI and severe AKI associated with ad-
ministration of hydroxocobalamin after adjustment for
potential confounding factors. Hydroxocobalamin was
not associated with improved survival.
Cyanide poisoning has been suspected to account
for deaths after smoke inhalation [12]. Hydroxocoba-
lamin (Cyanokit®, Merck Santé SAS) is approved by
the Food and Drug Administration for the treatment
of cyanide poisoning. Hydroxocobalamin chelates
cyanide to form cyanocobalamin, which is excreted by
the kidneys. Experts have advocated the use of cyan-
ide antidotes after smoke inhalation with suspected
cyanide intoxication. While preclinical data have sug-
gested improved hemodynamics with hydroxocobala-
min in animal models of cyanide intoxication, clinical
data are very limited. In two retrospective studies,
Borron et al. and Fortin et al. described the outcome
of patients receiving hydroxocobalamin after smoke
inhalation injury. However, the absence of control
groups precluded drawing any conclusion with respect
to the impact of hydroxocobalamin on outcome [13,
14]. Nguyen et al. reported that the use of hydroxo-
cobalamin was associated with fewer episodes of
pneumonia while mortality was unaffected [15]. How-
ever, the association between the prevention of pneu-
monia lies on very low level of evidence. Other
factors, especially with respect to pneumonia prevent-
ive strategies, may have accounted for the observation
of lower incidence of pneumonia in this before-and-
after retrospective study.
In the current study, we observed an association be-
tween hydroxocobalamin and the risk of AKI and severe
AKI. These results further suggest the potential nephro-
toxicity of the drug. We previously showed that hydro-
xocobalamin induces oxaluria with a risk of oxalate
nephropathy in burn patients [4]. Kidney biopsies con-
firmed renal calcium oxalate crystal deposits. Oxaluria
was also reported in healthy volunteers and animals re-
ceiving hydroxocobalamin [16]. Nitric oxide chelation
could represent an additional mechanism of renal tox-
icity of hydroxocobalamin. In the absence of cyanide,
hydroxocobalamin binds to nitric oxide. Nitric oxide is a
key factor of the renal microcirculatory regulation, and
inhibition of the nitric oxide pathway was shown to im-
pair renal perfusion and oxygenation and cause kidney
damage [17–19].
Cyanide is a rapidly lethal mitochondrial poison.
The plasma cyanide level is difficult to measure and
not readily available, and none of the patients in-
cluded in this study had a plasma cyanide dosage. In-
creased serum lactate level > 8 mmol/L was reported
to be a fair surrogate biomarker of cyanide poisoning
as a biomarker of mitochondrial dysfunction [10]. In
our study, hydroxocobalamin had no impact in the
subgroup of patients with high plasma lactate level.
The lack of evidence of any association between
hydroxocobalamin and survival in our study and the
risk of AKI question the risk-benefit ratio in these pa-
tients. Of note, hydroxocobalamin costs about €1000/
$1200 per vial.
We acknowledge the limitations of our study. First, the
retrospective nature introduced some bias. Performing a
randomized control trial in this setting would be highly
difficult due to the low incidence of smoke inhalation and
the existing cognitive biases toward the potential protect-
ive effects of hydroxocobalamin. Second, the relative low
number of patients with very high plasma lactate level pre-
cludes drawing firm conclusion in patients with a high
probability of cyanide poisoning and in most severe pa-
tients. Third, we could not confirm cyanide levels in any
patient, which makes it hard to determine if hydroxocoba-
lamin could benefit patients with confirmed cyanide poi-
soning. Finally, rhabdomyolysis may be a confounding
factor with the elevated serum creatinine. However, we
did not find any correlation between admission serum
creatinine, maximal serum creatinine at day 7 or during
hospitalization in ICU, and the pic of creatinine
phosphokinase.
Table 3 Patient characteristics (Continued)
Characteristics All patients, N = 739 Survivors, N = 496 Non-survivors, N = 243 p
- Aminoglycoside 188 (25.4) 115 (23.2) 73 (42.9) 0.0548
- Vancomycin 41 (5.5) 22 (4.4) 19 (7.8) 0.4011
- Contrast product 74 (10) 41 (8.3) 33 (13.6) 0.0331
All data are expressed as median ± 25–75 interquartile or percentage (%)
BMI body mass index, GCS Glasgow coma scale, CKD chronic kidney disease, CAOD chronic arterial occlusive disease, CHF chronic heart failure, TBSA total body
surface area, SOFA sequential organ failure assessment, MAP mean arterial pressure, HbCO carboxy hemoglobin, ICU intensive care unit, AKI acute kidney injury,
RRT renal replacement therapy, MAKE major associated kidney events, SAPS2 simplified acute physiology score 2
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Fig. 2 Unadjusted Kaplan–Meier curve of survival incidence during the 90 days following admission between patients who received
hydroxocobalamin and those who did not
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Conclusion
In this multicenter observational study of ICU patients
with smoke inhalation, administration of hydroxocobala-
min was independently associated with AKI and showed
no association with survival. The role of hydroxocobala-
min following smoke inhalation needs further consider-
ation and critical appraisal.
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